Moleculin Biotech is trading 5.2% up at $0.64 after opening-market strength on August 26, 2026, amid a broad biotech-sector rally.
- No company-specific announcement dated August 26 was identified.
- Its latest major update was the August 14 quarterly report, highlighting MIRACLE trial progress and positive preliminary efficacy results.
- Risk-on sentiment and recent Moderna-Merck cancer-vaccine optimism are supporting biotech stocks; a recent Zacks upgrade may provide background support but does not clearly explain today’s move.